Physician profile
Lauren G Moore
NPI 1407097470
$4,843.11
in general payments reported to CMS, 2019-2025
37 companies · $1,571 in 2025
The $1,571 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $289 · 2020: $199 · 2021: $347 · 2022: $689 · 2023: $682 · 2024: $1,065 · 2025: $1,571.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,317 · Education: $1.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,317.38 |
| Education | $1.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $947.06 | 2021-2025 | |
| Novo Nordisk INC | $538.00 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $390.01 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $281.72 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $243.10 | 2022-2025 | Caplyta |
| Astrazeneca Pharmaceuticals LP | $209.83 | 2019-2025 | Airsupra, Farxiga |
| Vanda Pharmaceuticals INC. | $207.12 | 2024-2025 | Fanapt |
| Axsome Therapeutics, INC. | $188.10 | 2023-2025 | Auvelity |
| Abbott Laboratories | $146.73 | 2021-2025 | Freestyle Libre 3 |
| Lundbeck LLC | $139.40 | 2021-2024 | Vyepti, Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $122.72 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $119.24 | 2019-2024 | Trintellix |
| Corium, LLC | $112.26 | 2023-2025 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $101.18 | 2023-2025 | Rexulti |
| Solventum Corporation | $96.74 | 2025 | Abthera, V.A.C. Veraflo |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $85.58 | 2019-2025 | |
| Amgen INC. | $84.92 | 2022-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $84.90 | 2022-2025 | Jascayd, Jardiance |
| Tris Pharma INC | $75.45 | 2023-2024 | Dyanavel Xr |
| Phathom Pharmaceuticals, INC. | $65.23 | 2024-2025 | Voquezna |
| Janssen Pharmaceuticals, INC | $64.03 | 2022-2025 | Spravato |
| Teva Pharmaceuticals USA, INC. | $56.43 | 2020 | |
| Amarin Pharma, INC. | $50.33 | 2020 | |
| Sanofi-Aventis U.S. LLC | $48.07 | 2021-2023 | |
| Idorsia Pharmaceuticals US INC | $45.97 | 2023-2024 | Quviviq |
| Dexcom, INC. | $45.03 | 2025 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.83 | 2019-2024 | Xifaxan |
| Allergan, INC. | $42.21 | 2019-2020 | |
| Exact Sciences Corporation | $40.61 | 2023-2024 | Cologuard Collection Kit |
| Optinose US, INC. | $36.50 | 2025 | |
| Alnylam Pharmaceuticals INC. | $30.95 | 2024 | Givlaari |
| Pacira Pharmaceuticals Incorporated | $24.33 | 2024 | Exparel |
| Mylan Specialty L.P. | $19.74 | 2021 | |
| Alkermes, INC. | $14.68 | 2025 | Aristada, Lybalvi |
| Collegium Pharmaceutical, INC. | $14.18 | 2025 | Jornay Pm |
| Hikma Pharmaceuticals USA | $13.18 | 2024 | Ryaltris |
| Merck Sharp & Dohme LLC | $12.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.